WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...

Those questions, experts say, are based on the Trump administration’s hawkish approach to China generally, as well as on a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

Nxera Pharma to get US$ 4.8 mn in milestone payments following Centessa’s initiation of clinical development of ORX142: Tokyo, Japan Monday, July 7, 2025, 14:00 Hrs [IST] Nxera ...